Comprehensive Healthcare Systems Secures New York City Based Client on Novus360 for Streamlined, High Value Utilization Management SolutionsJune 24, 2025 7:01 AM EDT | Source: Comprehensive Healthcare Systems Inc.Calgary, Alberta--(Newsfile Corp. - June 24, 2025) - Comprehensive Healthcare Systems Inc. (TSXV: CHS) (the "Company" or "CHS"), a leading provider of healthcare benefits administration software and services, is pleased to announce the expansion of its client portfolio with a 5 year r ...

Core Insights - Eni S.p.A. has entered exclusive negotiations with Global Infrastructure Partners to potentially sell a 49.99% co-control stake in its carbon capture, utilization, and storage subsidiary, Eni CCUS Holding [1][2] - The deal is part of Eni's strategy to accelerate investments in energy transition and unlock value from its decarbonization assets [2][5] - Eni CCUS Holding operates key carbon capture initiatives in the UK and the Netherlands, and holds future acquisition rights to the Ravenna CCS project in Italy, indicating strong market interest in CCUS [3][4] Company Strategy - The exclusivity period allows both Eni and GIP to complete due diligence and finalize transaction documentation [2] - GIP is expected to co-invest in expanding the CCUS platform, validating Eni's energy transition portfolio which includes renewable energy and low-carbon technologies [5] Project Developments - Eni has secured financing for the Liverpool Bay CCS project, which aims to capture CO2 emissions from industrial facilities in North West England and transport them for permanent storage beneath the Irish Sea [6] - Major EPC contracts have been awarded to Italian firms for the construction of CO2 compression stations and offshore platforms for long-term CO2 storage [7] Regulatory Context - Eni is among 44 oil and gas firms tasked by the EU to advance carbon storage initiatives, with a goal of injecting at least 50 million tons of CO2 annually by 2030, highlighting the urgency for CO2 storage solutions [8] - The timing of Eni's stake sale discussions reflects strong investor appetite for carbon management infrastructure as regulatory and climate ambitions intensify in Europe [8] Market Implications - Eni's potential partnership with GIP could serve as a model for legacy energy companies to monetize transition-related assets while leveraging external capital to scale their decarbonization efforts across Europe [9]

Core Viewpoint - iRhythm Technologies has launched its Zio long-term continuous ECG monitoring system in Japan, offering up to 14 days of uninterrupted ECG monitoring, which is a significant improvement over existing options in the market [1][4]. Company Overview - iRhythm Technologies, Inc. is a leading digital health care company focused on creating solutions that detect, predict, and prevent disease through wearable biosensors and cloud-based data analytics [14]. - The company has a strong commitment to improving patient outcomes, supported by over 125 original research manuscripts and insights from more than 2 billion hours of curated heartbeat data [7]. Product Details - The Zio ECG Recording and Analysis System includes a patch-based ECG monitoring device that can be worn for up to 14 days and utilizes a deep-learned AI algorithm approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) [3][5]. - The system demonstrates 99% patient compliance with prescribed wear time and 99% analyzable data, providing high-quality, actionable insights [5]. - The Zio service is associated with the highest diagnostic yield and lowest likelihood of retesting compared to other monitoring services, including Holter monitoring [5]. Market Opportunity - Japan is the second largest ambulatory cardiac monitoring market globally, with an estimated 1.6 million tests prescribed annually, a number expected to rise due to the aging population and increasing prevalence of cardiac arrhythmias [10][11]. - The launch of the Zio system is timely, addressing the growing demand for early and accurate detection of arrhythmias in Japan [4]. Clinical Validation - The clinical value of the Zio LTCM service has been validated through studies, including the CAMELOT study, which found it to be associated with the highest yield of specified arrhythmia diagnosis and the lowest likelihood of repeat testing [6][8]. - The Zio service combines advanced AI with expert clinical review to support accurate and timely diagnoses, enhancing patient care [8]. Distribution and Availability - The Zio ECG Recording and Analysis System will be available to healthcare customers in Japan starting May 2025, with nationwide availability expected by July 2025, through Senko Medical Instrument, the exclusive distribution partner [12].